1,343 Shares in Stryker Co. (NYSE:SYK) Acquired by Investor s Fiduciary Advisor Network LLC

Investor s Fiduciary Advisor Network LLC purchased a new position in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,343 shares of the medical technology company's stock, valued at approximately $483,000.

Several other institutional investors have also modified their holdings of SYK. Norges Bank purchased a new stake in Stryker in the fourth quarter valued at $1,710,744,000. Raymond James Financial Inc. purchased a new stake in Stryker in the fourth quarter valued at $353,394,000. FMR LLC lifted its position in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC lifted its position in Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock valued at $214,660,000 after acquiring an additional 595,061 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SYK. Stifel Nicolaus boosted their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Wells Fargo & Company boosted their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, BTIG Research set a $403.00 target price on shares of Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $427.05.

Stryker Price Performance

Shares of NYSE:SYK traded up $6.10 during trading on Thursday, hitting $392.42. 1,124,420 shares of the stock were exchanged, compared to its average volume of 1,349,714. The company has a market cap of $149.78 billion, a PE ratio of 50.57, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average price of $365.58 and a two-hundred day moving average price of $374.90. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the business earned $2.50 earnings per share. The company's quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker's dividend payout ratio is currently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.